Access the full text.
Sign up today, get DeepDyve free for 14 days.
T. Powles, R. Eeles, S. Ashley, D. Easton, Jenny Chang, M. Dowsett, A. Tidy, J. Viggers, J. Davey (1998)
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trialThe Lancet, 352
V. Jordan (1976)
Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata.European journal of cancer, 12 6
A. Coates, A. Keshaviah, B. Thürlimann, H. Mouridsen, L. Mauriac, J. Forbes, R. Paridaens, M. Castiglione‐Gertsch, R. Gelber, M. Colleoni, I. Láng, L. Mastro, I. Smith, J. Chirgwin, J. Nogaret, T. Pieńkowski, A. Wardley, E. Jakobsen, K. Price, A. Goldhirsch (2007)
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 5
E. Barrett-Connor, L. Mosca, P. Collins, M. Geiger, D. Grady, M. Kornitzer, M. McNabb, N. Wenger (2006)
Adult Weight Change and Risk of Postmenopausal Breast CancerObstetrics & Gynecology, 108
V. Vogel, J. Costantino, D. Wickerham, W. Cronin, R. Cecchini, J. Atkins, T. Bevers, L. Fehrenbacher, E. Pajon, J. Wade, A. Robidoux, R. Margolese, J. James, S. Lippman, C. Runowicz, P. Ganz, S. Reis, W. McCaskill-Stevens, L. Ford, V. Jordan, N. Wolmark (2006)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.JAMA, 295 23
A. Howell, J. Cuzick, M. Baum, A. Buzdar, M. Dowsett, J. Forbes, G. Hoctin-Boes, J. Houghton, G. Locker, J. Tobias (2005)
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancerThe Lancet, 365
U. Veronesi, P. Maisonneuve, Alberto Costa, V. Sacchini, C. Maltoni, C. Robertson, N. Rotmensz, P. Boyle (1998)
Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised womenThe Lancet, 352
U. Veronesi, L. Mariani, A. Decensi, F. Formelli, T. Camerini, R. Miceli, M. Mauro, Aurora Costa, E. Marubini, M. Sporn, G. Palo (2006)
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 17 7
Barrett-Connor (2006)
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal womenNew England Journal of Medicine, 355
S. Martino, J. Cauley, E. Barrett-Connor, T. Powles, J. Mershon, D. Disch, R. Secrest, S. Cummings (2004)
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.Journal of the National Cancer Institute, 96 23
H. Mouridsen, M. Gershanovich, Yan Sun, R. Pérez-Carrión, C. Boni, A. Monnier, J. Apffelstaedt, Robert Smith, H. Sleeboom, F. Jänicke, A. Płużańska, M. Dank, D. Becquart, P. Bapsy, E. Salminen, R. Snyder, M. Lassus, J. Verbeek, Beatrix Staffler, H. Chaudri-Ross, M. Dugan (2001)
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 10
R. Jakesz, W. Jonat, M. Gnant, M. Mittlboeck, R. Greil, C. Tausch, J. Hilfrich, W. Kwasny, C. Menzel, H. Samonigg, M. Seifert, G. Gademann, M. Kaufmann (2005)
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trialThe Lancet, 366
De-Kun Li, Marian Willinger, Diana Petitti, R. Odouli, Liyan Liu, Howard Hoffman (2005)
Use of a dummy (pacifier) during sleep and risk of sudden infant death syndrome (SIDS): population based case-control studyBMJ : British Medical Journal, 332
L. Rutqvist, B. Cedermark, U. Glas, A. Mattsson, L. Skoog, A. Somell, T. Theve, N. Wilking, J. Askergren, M. Hjalmar, S. Rotstein, L. Perbeck, U. Ringborg (1991)
Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy.Journal of the National Cancer Institute, 83 18
R. Chlebowski, N. Col, E. Winer, D. Collyar, S. Cummings, V. Vogel, H. Burstein, A. Eisen, I. Lipkus, D. Pfister (2002)
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 15
R. Peto, J. Boreham, M. Clarke, C. Davies, V. Beral (2000)
UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 yearsThe Lancet, 355
Thurlimann (2005)
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancerNew England Journal of Medicine, 353
R. Coombes, L. Kilburn, C. Snowdon, R. Paridaens, R. Coleman, Stephen Jones, J. Jassem, C. Velde, T. Delozier, I. Álvarez, L. Mastro, O. Ortmann, K. Diedrich, A. Coates, E. Bajetta, S. Holmberg, D. Dodwell, E. Mickiewicz, J. Andersen, P. Lønning, G. Cocconi, J. Forbes, M. Castiglione, N. Stuart, A. Stewart, L. Fallowfield, G. Bertelli, E. Hall, R. Bogle, M. Carpentieri, E. Colajori, M. Subar, E. Ireland, J. Bliss (2007)
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialThe Lancet, 369
M. Baum, A. Budzar, J. Cuzick, J. Forbes, J. Houghton, J. Klijn, T. Sahmoud (2002)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 359
T. Powles, S. Ashley, A. Tidy, I. Smith, M. Dowsett (2007)
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.Journal of the National Cancer Institute, 99 4
S. Cykert, Nancy Phifer, C. Hansen (2004)
Tamoxifen for Breast Cancer Prevention: A Framework for Clinical DecisionsObstetrics & Gynecology, 104
M. Ellis, A. Coop, Baljit Singh, L. Mauriac, Antonio Llombert-Cussac, F. Jänicke, W. Miller, D. Evans, M. Dugan, C. Brady, E. Quebe‐Fehling, M. Borgs (2001)
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 18
J. Cuzick, T. Powles, U. Veronesi, J. Forbes, R. Edwards, S. Ashley, P. Boyle (2003)
Overview of the main outcomes in breast-cancer prevention trialsThe Lancet, 361
A. Guerrieri-Gonzaga, C. Robertson, B. Bonanni, D. Serrano, M. Cazzaniga, S. Mora, M. Gulisano, H. Johansson, F. Formelli, M. Intra, A. Latronico, D. Franchi, G. Pelosi, K. Johnson, A. Decensi (2006)
Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 1
W. Jonat, M. Gnant, F. Boccardo, M. Kaufmann, A. Rubagotti, I. Zuna, M. Greenwood, R. Jakesz (2006)
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis.The Lancet. Oncology, 7 12
U. Veronesi, G. Palo, E. Marubini, A. Costa, F. Formelli, L. Mariani, A. Decensi, T. Camerini, M. Turco, M. Mauro, M. Muraca, M. Vecchio, C. Pinto, G. D'Aiuto, C. Boni, T. Campa, A. Magni, R. Miceli, M. Perloff, W. Malone, M. Sporn (1999)
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.Journal of the National Cancer Institute, 91 21
E. Honrado, A. Osorio, J. Palacios, J. Benítez (2006)
Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutationsOncogene, 25
J. Ingle, D. Tu, J. Pater, S. Martino, N. Robert, H. Muss, M. Piccart, M. Castiglione, L. Shepherd, K. Pritchard, R. Livingston, N. Davidson, L. Norton, E. Perez, J. Abrams, D. Cameron, M. Palmer, P. Goss (2006)
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trialBreast Cancer Research and Treatment, 99
E. Winer, C. Hudis, H. Burstein, A. Wolff, K. Pritchard, J. Ingle, R. Chlebowski, R. Gelber, S. Edge, J. Gralow, M. Cobleigh, E. Mamounas, L. Goldstein, T. Whelan, T. Powles, J. Bryant, Cheryl Perkins, J. Perotti, S. Braun, A. Langer, G. Browman, M. Somerfield (2002)
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 3
J. Geisler, S. Detre, H. Berntsen, L. Ottestad, B. Lindtjørn, M. Dowsett, P. Lønning (2001)
Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 5
S. Narod, J. Brunet, P. Ghadirian, M. Robson, K. Heimdal, S. Neuhausen, D. Stoppa-Lyonnet, C. Lerman, B. Pasini, P. Rios, B. Weber, H. Lynch (2000)
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control studyThe Lancet, 356
P. Goss, J. Ingle, S. Martino, N. Robert, H. Muss, M. Piccart, M. Castiglione, D. Tu, L. Shepherd, K. Pritchard, R. Livingston, N. Davidson, L. Norton, E. Perez, J. Abrams, D. Cameron, M. Palmer, J. Pater (2005)
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.Journal of the National Cancer Institute, 97 17
Umberto Veronesi, Patrick Maisonneuve, Virgilio Sacchini, N. Rotmensz, Peter Boyle (2002)
Tamoxifen for breast cancer among hysterectomised womenThe Lancet, 359
Jane Cauley, L. Norton, Marc Lippman, S. Eckert, Kathryn Krueger, David Purdie, J. Farrerons, A. Karasik, D. Mellstrom, Kong Ng, Jan Stepan, T. Powles, M. Morrow, Alberto Costa, S. Silfen, E. Walls, H. Schmitt, D. Muchmore, V. Jordan (2004)
Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE TrialBreast Cancer Research and Treatment, 65
B. Fisher, J. Costantino, D. Wickerham, R. Cecchini, W. Cronin, A. Robidoux, T. Bevers, M. Kavanah, J. Atkins, R. Margolese, C. Runowicz, J. James, L. Ford, N. Wolmark, N. Wolmark (2005)
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.Journal of the National Cancer Institute, 97 22
E. Jolly, N. Bjarnason, P. Neven, L. Plouffe, C. Johnston, S. Watts, C. Arnaud, T. Mason, G. Crans, R. Akers, M. Draper (2003)
Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 yearsMenopause, 10
J. Nabholtz, J. Bonneterre, Aman Buzdar, J. Robertson, B. Thürlimann (2003)
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results.European journal of cancer, 39 12
U. Veronesi, P. Maisonneuve, N. Rotmensz, Alberto Costa, V. Sacchini, R. Travaglini, G. D'aiuto, F. Lovison, G. Gucciardo, M. Muraca, M. Pizzichetta, S. Conforti, A. Decensi, C. Robertson, P. Boyle (2003)
Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.Journal of the National Cancer Institute, 95 2
M. Dowsett, A. Jones, S. Johnston, S. Jacobs, P. Trunet, I. Smith (1995)
In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 1 12
J. Cuzick, J. Forbes, I. Šestak, S. Cawthorn, H. Hamed, K. Holli, A. Howell (2007)
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.Journal of the National Cancer Institute, 99 4
Despite recent advances in the surgical and medical treatment of breast cancer, the number of patients dying from the disease is still high. In addition to improvements of early diagnosis and treatment, the overall mortality of breast cancer could be reduced by means of preventive intervention in both women with particularly normal and with high risk. Preventing the potentially deadly disease is presumably more effective than treatment, for life quality issues as well as for the economic perspective. Chemoprevention though is still a research field with results from large prevention trials being discussed controversially. For women with a defined increased risk for breast cancer, tamoxifen may be a choice for chemoprevention, balancing carefully benefits against risks. With promising results in adjuvant settings, aromatase inhibitors may deliver better prevention treatment options in the future, nevertheless, more research is needed to reliably predict risk on an individual basis in the future.
European Journal of Cancer Care – Wiley
Published: Sep 1, 2009
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.